NASDAQ:PSTX Poseida Therapeutics (PSTX) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free PSTX Stock Alerts $2.99 +0.09 (+3.10%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.90▼$3.0350-Day Range$2.00▼$3.4652-Week Range$1.54▼$4.27Volume173,685 shsAverage Volume438,854 shsMarket Capitalization$289.91 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Poseida Therapeutics alerts: Email Address Poseida Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside390.5% Upside$14.67 Price TargetShort InterestHealthy5.19% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment1.26Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.61) to ($1.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.94 out of 5 starsMedical Sector210th out of 928 stocksBiological Products, Except Diagnostic Industry24th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingPoseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePoseida Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Poseida Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.19% of the outstanding shares of Poseida Therapeutics have been sold short.Short Interest Ratio / Days to CoverPoseida Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Poseida Therapeutics has recently decreased by 16.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePoseida Therapeutics has received a 73.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Poseida Therapeutics is -0.93. Previous Next 3.5 News and Social Media Coverage News SentimentPoseida Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Poseida Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for PSTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Poseida Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Poseida Therapeutics is held by insiders.Percentage Held by Institutions46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Poseida Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Poseida Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Poseida Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPoseida Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Poseida Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only financial event in 2024 that matters Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral.Stream the documentary for free by clicking here About Poseida Therapeutics Stock (NASDAQ:PSTX)Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More PSTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTX Stock News HeadlinesMay 25, 2024 | americanbankingnews.comPoseida Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.43) Per Share, HC Wainwright Forecasts (NASDAQ:PSTX)May 24, 2024 | americanbankingnews.comPoseida Therapeutics, Inc. Forecasted to Earn Q3 2025 Earnings of ($0.49) Per Share (NASDAQ:PSTX)May 23, 2024 | americanbankingnews.comPoseida Therapeutics' (PSTX) "Buy" Rating Reaffirmed at HC WainwrightMay 15, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024May 14, 2024 | investorplace.comPSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | prnewswire.comPoseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024May 9, 2024 | prnewswire.comPoseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingMay 3, 2024 | finance.yahoo.comBroker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging HigherMay 2, 2024 | markets.businessinsider.comStrategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida TherapeuticsMay 2, 2024 | markets.businessinsider.comStrong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing CapabilitiesMay 1, 2024 | markets.businessinsider.comStrategic Partnership Boosts Poseida Therapeutics’ Solid Tumor Treatment Capabilities and Underpins Buy RatingMay 1, 2024 | markets.businessinsider.comAstellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In OncologyMay 1, 2024 | prnewswire.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyMay 1, 2024 | marketwatch.comPoseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos BiosciencesMay 1, 2024 | msn.comBiotech Soars on Research Collaboration And License Agreement ReleaseMay 1, 2024 | msn.comPoseida gains on cell therapy pact with AstellasMay 1, 2024 | finance.yahoo.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyApril 18, 2024 | prnewswire.comPoseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 17, 2024 | finance.yahoo.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 17, 2024 | prnewswire.comPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 16, 2024 | msn.comPalisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare moversApril 9, 2024 | investing.comPoseida reports promising results for myeloma therapyApril 8, 2024 | prnewswire.comPoseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaApril 1, 2024 | prnewswire.comPoseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerSee More Headlines Receive PSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today6/01/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PSTX CUSIPN/A CIK1661460 Webwww.poseida.com Phone858-779-3100FaxN/AEmployees335Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+390.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,430,000.00 Net Margins-131.95% Pretax Margin-131.82% Return on Equity-97.36% Return on Assets-38.88% Debt Debt-to-Equity Ratio0.69 Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual Sales$64.70 million Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book3.44Miscellaneous Outstanding Shares96,960,000Free Float94,146,000Market Cap$289.91 million OptionableOptionable Beta0.46 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark J. Gergen J.D. (Age 61)Executive Chairman of the Board Comp: $961.8kDr. Kristin Yarema Ph.D. (Age 53)President, CEO & Director Comp: $711.99kMs. Johanna M. Mylet CPA (Age 36)Chief Financial Officer Mr. Loren WagnerChief Operations OfficerMs. Kristin MartinChief People & Administration OfficerMr. Alexander ChapmanSenior VP of Investor Relations & Corporate CommunicationsMr. Harry J. Leonhardt Esq. (Age 67)J.D., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $630.23kDr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell TherapyMs. Lisa PortaleSenior Vice President of Regulatory AffairsDr. Jeffrey W. Winkelman J.D.Ph.D., Senior VP & Chief Patent CounselMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPAthira PharmaNASDAQ:ATHAPrecision BioSciencesNASDAQ:DTILPassage BioNASDAQ:PASGAligos TherapeuticsNASDAQ:ALGSView All CompetitorsInstitutional OwnershipJacobs Levy Equity Management Inc.Bought 391,801 shares on 5/16/2024Ownership: 0.856%Bayesian Capital Management LPBought 10,200 shares on 5/16/2024Ownership: 0.011%Public Employees Retirement System of OhioBought 40,245 shares on 5/15/2024Ownership: 0.065%Lazard Asset Management LLCBought 21,138 shares on 5/15/2024Ownership: 0.030%Acadian Asset Management LLCSold 136,201 shares on 5/10/2024Ownership: 0.377%View All Institutional Transactions PSTX Stock Analysis - Frequently Asked Questions Should I buy or sell Poseida Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTX shares. View PSTX analyst ratings or view top-rated stocks. What is Poseida Therapeutics' stock price target for 2024? 3 analysts have issued 1-year target prices for Poseida Therapeutics' shares. Their PSTX share price targets range from $10.00 to $20.00. On average, they expect the company's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 390.5% from the stock's current price. View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts. How have PSTX shares performed in 2024? Poseida Therapeutics' stock was trading at $3.36 on January 1st, 2024. Since then, PSTX shares have decreased by 11.0% and is now trading at $2.99. View the best growth stocks for 2024 here. Are investors shorting Poseida Therapeutics? Poseida Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 5,030,000 shares, a decrease of 16.7% from the April 30th total of 6,040,000 shares. Based on an average daily volume of 700,400 shares, the days-to-cover ratio is presently 7.2 days. View Poseida Therapeutics' Short Interest. When is Poseida Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PSTX earnings forecast. How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.09. The business had revenue of $25 million for the quarter, compared to analysts' expectations of $12.50 million. Poseida Therapeutics had a negative net margin of 131.95% and a negative trailing twelve-month return on equity of 97.36%. What ETFs hold Poseida Therapeutics' stock? ETFs with the largest weight of Poseida Therapeutics (NASDAQ:PSTX) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA).Global X Genomics & Biotechnology ETF (GNOM). What other stocks do shareholders of Poseida Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM). When did Poseida Therapeutics IPO? Poseida Therapeutics (PSTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO. Who are Poseida Therapeutics' major shareholders? Poseida Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.48%), Blair William & Co. IL (1.00%), Jacobs Levy Equity Management Inc. (0.86%), Acadian Asset Management LLC (0.38%), Public Employees Retirement System of Ohio (0.06%) and Russell Investments Group Ltd. (0.04%). Insiders that own company stock include Eric Ostertag, Kerry D Ingalls, Life Sciences Holdings L Malin and Matthew A Spear. View institutional ownership trends. How do I buy shares of Poseida Therapeutics? Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSTX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
